In Thursday’s Wall Street session, Checkpoint Therapeutics Inc (NASDAQ:CKPT) shares traded at $4.26, up 0.71% from the previous session.
CKPT stock price is now 4.14% away from the 50-day moving average and 28.27% away from the 200-day moving average. The market capitalization of the company currently stands at $370.70M.
With the price target of $9, D. Boral Capital recently initiated with Buy rating for Checkpoint Therapeutics Inc (NASDAQ: CKPT). , while ‘Cantor Fitzgerald’ rates the stock as ‘Overweight’
In other news, Oliviero James F III, CEO, President and Director sold 15,090 shares of the company’s stock on Apr 02 ’25. The stock was sold for $60,964 at an average price of $4.04. Upon completion of the transaction, the CEO, President and Director now directly owns 3,759,929 shares in the company, valued at $16.02 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Apr 01 ’25, Chief Financial Officer GRAY WILLIAM GARRETT sold 12,322 shares of the business’s stock. A total of $49,904 was realized by selling the stock at an average price of $4.05. This leaves the insider owning 1,446,322 shares of the company worth $6.16 million. A total of 14.80% of the company’s stock is owned by insiders.
During the past 12 months, Checkpoint Therapeutics Inc has had a low of $1.75 and a high of $4.50. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 1.91, and a quick ratio of 1.91.
The net profit margin was -137821.95% and return on equity was -1869.55% for CKPT.
